Ann Kristin Led, former Exec. Vice President of Finance and Strategy at pharma company MC2 Therapeutics, is the new CFO at MedTrace from April 1. She will join CEO Martin Stenfeldt and COO Rune Wiik Kristensen as part of management and play a vital role in the fast scaling of the company towards commercialization in the USA, MedTrace’s future key market.
Danish pharma company MedTrace is in a transformation process. With four clinical partners onboard in Europe and FDA’s approval to commence the company’s phase III trial, MedTrace is on its way to broader commercialization.
This is where Ann Kristin Led steps in – a heavyweight financial strategist with 15 years of experience in the financial part of the pharmaceuticals industry. Before MC2 Therapeutics, her most recent position, where she spent three years as Exec. Vice President of Finance and Strategy, she spent 11 years at Danish pharma company Lundbeck. Most recently, in the role of Director of Business Development.
“I am stepping in at a fascinating time in the history of MedTrace. The company has an innovative product that is well on its way to full commercialization and a well-structured organization full of highly dedicated and talented people. From a financial perspective, this is an ideal platform to build from, and I’m excited about the challenges ahead and the successes that I hope we will share as a team”, says Ann Kristin Led, the newly appointed CFO of MedTrace.
Martin Stenfeldt, CEO of MedTrace, is happy to finally welcome Ann Kristin Led after a long search for just the right candidate.
“As a financial talent and person, Ann Kristin Led is a highly valued expansion of the MedTrace family. We are moving at a pace that calls for a dedicated financial strategist with industry knowledge, the skillset to tackle both numbers and strategy, and the ability to build and nurture our investor relations. We have that in Ann Kristin Led. In addition, I look forward to the new perspectives and skills that she will add to our management team”, says Martin Stenfeldt, CEO at MedTrace.
Ann Kristin Led’s key focus will be to finetune and expand MedTrace’s financial function and manage investor relations. In addition, she steps into the management team alongside CEO Martin Stenfeldt and COO Rune Wiik Kristensen, who have joined forces since the founding of MedTrace in 2015.
By MedTrace, Press Release
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.